title: The impact of the US priority review voucher on private-sector investment in global health research and development.
authors.affiliation: BIO Ventures for Global Health, San Francisco, California, United States of America.
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Robertson
authors.forename: Rianna
authors.initials: R
authors.lastname: Stefanakis
authors.forename: Don
authors.initials: D
authors.lastname: Joseph
authors.forename: Melinda
authors.initials: M
authors.lastname: Moree
mesh_terms: D035843:Biomedical Research / Q000191:economics / Q000639:trends*; D003141:Communicable Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D014943:Global Health; D006291:Health Policy; D006801:Humans; D017053:Infection Control / Q000379:methods; D007449:Investments / Q000706:statistics & numerical data* / Q000639:trends; D058069:Neglected Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control* / Q000628:therapy; D017149:Private Sector / Q000191:economics / Q000706:statistics & numerical data* / Q000639:trends; D012106:Research / Q000191:economics / Q000639:trends*; D014481:United States